Search
Align Summit 2026: Unravel Biosciences spun out of Harvard's Wyss Institute and is using AI to analyze patient RNA samples to find existing compounds that can make a difference in rare disease
Co-Founder & CEO Richard Novak describes the screening process and the benefits of focusing on existing compounds for which the profile is already largely known. The lead program is already in the clinic for Rett syndrome and Pitt Hopkins syndrome. Coverage brought to you by
4 hours ago
.png){kind=logo}